Research showing cardiac risk for HIV drug results in FDA warning
October 28, 2016 – A newly published study has shown that an antiviral drug commonly used to treat HIV can cause heart abnormalities in people who have a genetic mutation in the enzyme that metabolizes the medication, potentially leading to sudden cardiac death.
Studies initially performed by researchers at Purdue University's College of Pharmacy and Indiana University's School of Medicine showed the drug efavirenz might cause a form of heart arrhythmia called torsade de pointes. Based on these findings, the drug's manufacturer performed further research, which confirmed the initial findings. The U.S. Food and Drug Administration recently approved updated labeling for the drug, marketed as Sustiva by Bristol-Myers Squibb, to include a warning regarding the risk. Continuing reading here.